Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity

Item

http://www.wikidata.org/entity/Q33729078

Q33729078

about

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer Muscle-invasive urothelial bladder cancer: an update on systemic therapy Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.Systemic therapy for bladder cancer finally comes into a new age.Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.Systemic therapy in bladder cancer Critically short telomeres and toxicity of chemotherapy in early breast cancer The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.Isoliensinine induces apoptosis in triple-negative human breast cancer cells through ROS generation and p38 MAPK/JNK activation.Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer.The role of genomics in the management of advanced bladder cancer.Targeting Signaling Transduction Pathways in Bladder Cancer.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.Treatment of muscle-invasive bladder cancer: A systematic review.Chemotherapy for Muscle-Invasive Bladder Cancer.Dose dense MVAC prior to radical cystectomy: a real-world experience.A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, an Improving Systemic Chemotherapy for Bladder Cancer.Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy.Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology.Contemporary update on neoadjuvant therapy for bladder cancer.Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.Predicting response to neoadjuvant chemotherapy in bladder cancer: controversies remain with genomic DNA sequencing Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy.Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017.Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer.Detection of circulating tumor DNA for advanced bladder cancer: where are we going?

P2860

Q26773664-B4D60ABF-68DE-4783-A16E-A98D29373CA1 Q26775780-69CBDF49-A179-46EE-83A1-2158F44C9834 Q27024948-651CCB66-5DEA-4D1C-A6E5-30C216A6C17E Q28084715-8027A8FF-5670-4746-8CD5-85D6EEA79B88 Q30240816-C55B1F22-9E00-4189-9845-89A59EA8110F Q30249047-D798C33F-B243-4B60-84B6-64B7DD673E2E Q33441139-B76E9542-AEC1-4FD9-9639-F6D7DD68D00F Q33578564-331DA582-1EAD-4CA0-B870-E2B95125A0DF Q33591567-E9A03C17-5BDB-4B85-9FDC-2ED92883E389 Q33886353-F8E8D460-0DD0-4913-972B-9DB2F7764235 Q35866471-9E4EA6D1-3145-42C2-9A47-BCFAD771D0BC Q35898217-751425EF-54AE-4DE4-9754-247E3F9DE2E2 Q36608587-B1B5B963-B317-467C-853C-B4FC03ED83F5 Q37736774-91FAA7AD-E8A0-4A12-B4D9-29B2AEA569C4 Q38325864-3B578ECE-72C7-4572-B11C-D074895EE52E Q38342992-664D63FE-81EE-41EE-9F4B-7F84D8512C95 Q38608540-230949CE-E9E3-457E-82FA-CF84A1F098E3 Q38613025-E3EA9B3E-850B-4B79-BC42-834FD0A02EBE Q38661975-C85CEBE4-0EB9-4CFF-9462-A925FDEFF5D8 Q38698579-E407BEA0-46BC-4297-B4C7-C5BBFB1D9B60 Q38711504-E60F17CF-1E85-412C-9B8E-5A69AD438C80 Q38720755-855A9B19-C26E-4DB9-9D31-72651EEC8294 Q38732403-C2B6984E-97F5-4D21-9072-B69EE912B492 Q38777610-2F84CF77-195D-4C23-9D20-CC5C76625D6A Q38800274-9EA88EB6-9EFE-4E84-892C-ADFC42287A91 Q38836010-1D2CAB2E-9044-4814-869A-ABCFF51A14C2 Q38852690-B6DD2C6E-985D-45F3-B233-C160A507375C Q38859015-DF22CA5C-3882-4812-AEDC-5AF07CEF5F90 Q39177293-10D3D03C-3D29-4B06-B324-1805878CB2E9 Q39790653-C2EB409D-50F2-4297-A7DD-51D5144FCD1A Q40368151-68327DA1-71BE-4555-AFD9-D5C63E9B798A Q41074322-EAF770EC-5BEE-49F5-82D6-B4ADB6140582 Q42237719-C05AE42D-08D6-4F6A-9BC0-74D12FF88244 Q47111129-6F0BD2EB-671F-4018-8852-C60680F77BF0 Q49526759-07158FEB-01DC-4B99-8B37-B3A4024879E9 Q53422101-3152C550-3C73-4FDC-91B1-2F91EE9BCBBD Q54004930-3B6B31C3-B5E1-42ED-9888-A7283D003009 Q54935962-11C66219-9D10-4EDC-9FF4-0B34DBC0199E

P2860

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity

Item

http://www.wikidata.org/entity/Q33729078

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu